Our results do not completely solve the puzzling lack of effect of PD1/PD-L1 inhibitors in triple-negative breast cancer but do suggest future research directions to find more accurate predictive markers for prescribing immunotherapy and to obtain more clinical benefit. Here, PDCD1 is linked to triple-negative breast carcinoma.